Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity

Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs

May 10th 2025

By Deana Ferreri, PhD

Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.

Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars

May 9th 2025

By Skylar Jeremias

The Top 5 Biosimilar Articles for the Week of May 5

May 9th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of May 5, 2025.

Targeted Reimbursement Encourages Oncology Biosimilar Use

May 7th 2025

By Skylar Jeremias

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow

May 6th 2025

By Cameron Santoro

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

BioRationality: A New Bill to Transform the Future of Biosimilars

May 5th 2025

By Sarfaraz K. Niazi, PhD

Escaping the Void: All Things Biosimilars With Craig & G

May 4th 2025

By Craig Burton

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."

Future Directions for Ustekinumab Biosimilars in Crohn Disease

May 3rd 2025

By Deana Ferreri, PhD

The Top 5 Biosimilar Articles for the Week of April 28

May 2nd 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of April 28, 2025.

Samsung Bioepis Report Signals Turning Point for US Biosimilars

May 1st 2025

By Skylar Jeremias

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.